Viloxazine: Difference between revisions

(12 intermediate revisions by 3 users not shown)

Line 1:

{{MedTemplate

| ~~generic~~ ~~= Viloxazine~~

| brand = Qelbree

~~| brand~~ = Qelbree

| classes = Selective norepinephrine reuptake inhibitor (NRI) with 5HT1A partial agonism, non-stimulant ADHD agent

| classes = NRI, ADHD ~~medicine~~

| mechanism = Selective NET inhibitor (no significant DAT activity, distinguishes from amphetamine/methylphenidate). Also: 5HT1A receptor partial agonism, 5HT2B and 5HT7 receptor antagonism. The serotonergic actions may underlie better tolerability and possibly different efficacy spectrum than atomoxetine.

| mechanism = ~~Selective~~ norepinephrine reuptake inhibitor

| uses = ADHD in children (6+), adolescents, and adults (FDA-approved 2021 for pediatric, 2022 for adult)

| starting_dose = Pediatric 6-11: 100 mg PO daily, titrate weekly to max 400 mg. Adolescent 12-17: 200 mg, max 400 mg. Adult: 200 mg, max 600 mg.

| preparations = 100 mg, 150 mg, 200 mg extended-release capsules (can be sprinkled on food)

| fda_max = 400 mg/d (pediatric); 600 mg/d (adult)

| routes = Oral

| onset = ADHD symptom improvement reported within 1-2 weeks (faster than atomoxetine which takes 4-6 weeks)

| duration = Daily dosing

| halflife = ~7 hours

| bioavailability = Adequate oral bioavailability with extended-release formulation

| pregnancy = Limited data

| legal = Rx, '''not a controlled substance''' (no DEA scheduling)

| intro = '''Viloxazine''' (brand name Qelbree) is an extended-release norepinephrine reuptake inhibitor FDA-approved in 2021 for ADHD in children 6 and older, and in 2022 for adults. Originally developed as an antidepressant in Europe in the 1970s (withdrawn for commercial reasons), it was repurposed for ADHD. Like atomoxetine, viloxazine is a non-stimulant alternative that is '''not a controlled substance'''. However, viloxazine has a more complex pharmacology than atomoxetine, beyond pure NET inhibition, it has 5HT1A partial agonism and 5HT2B/5HT7 antagonism, which may underlie faster onset (1-2 weeks vs atomoxetine's 4-6 weeks) and possibly different efficacy.

Useful when stimulants are contraindicated, undesirable, or insufficient. Can be combined with stimulants.

| pharmacodynamics= Selective NET inhibition (Ki ~155 nM). 5HT1A partial agonism, 5HT2B antagonism, 5HT2C inverse agonism, 5HT7 antagonism. Minimal DAT activity (key differentiator from stimulants).

| effects = Somnolence (most common), decreased appetite, headache, insomnia, fatigue, nausea, irritability. Generally good tolerability. Boxed warning: suicidal ideation in pediatric patients (class warning for SNRIs/antidepressants used in pediatric ADHD).

| interactions = <pharmaInteractions/>

}}

~~[[Category:Psychostimulants]]~~

[[Category:Norepinephrine Reuptake Inhibitors (NRIs)]]

[[Category:Antidepressants]]

[[Category:Non-stimulant ADHD Medicines]]

MDElliottMD (talk | contribs)